Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending February 23, 2017. The document serves as a transaction notification regarding insider trading activities by Persons Discharging Managerial Responsibilities (PDMRs) and persons closely associated with them (PCAs).
Key Financial Metrics
The filing does not contain consolidated financial statements, revenue, profit, cash flow, margin, debt, or liquidity metrics. It exclusively reports specific share transaction details:
- Instrument: GlaxoSmithKline plc American Depositary Shares (ADSs), ISIN: US37733W1053.
- Transaction Date: February 22, 2017.
- Transaction Price: $41.03 per ADS.
- Total Volume Reported: 66 ADSs (53 ADSs for Dr. M M Slaoui and 13 ADSs for Dr. K Slaoui).
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document details an increase in ADS holdings for two individuals resulting from the notional allocation of ADSs within the GSK 401(K) plan due to the revaluation of the cash element of their notional investments.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It is a regulatory disclosure of specific share transactions.
Investor Verification Checklist
- Verify the identity of the PDMR (Dr. M M Slaoui, Chairman, Global Vaccines) and the associated PCA (Dr. K Slaoui).
- Confirm the transaction nature as a notional allocation within the 401(K) plan rather than an open market purchase.
- Check the transaction price of $41.03 against the market price of GSK ADSs on February 22, 2017.
- Note that this filing does not provide data on GSK's overall financial performance for the period.